>

MEETINGS / EVENTS

RSS

November 08 - 09 2014, 12:00 AM - 12:00 AM

ASA Quality Meeting 2014

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

October 16, 2014

FDA MedWatch - LifeCare Flexible Intravenous Solutions by Hospira, Inc.: Recall - Potential for Leakage

Summary:

FDA MedWatch LifeCare Flexible Intravenous Solutions by Hospira Inc

October 13, 2014

FDA MedWatch - CareFusion EnVe and ReVel Ventilators: Class 1 Recall - Power Connection Failure

Summary:

FDA MedWatch CareFusion EnVe and ReVel Ventilators

October 13, 2014

FDA MedWatch - ICU Medical ConMed Stat2 Flow Controller: Class 1 Recall - Delivers Higher Flow Rate than Intended

Summary:

FDA MedWatch ICU Medical ConMed Stat2 Flow Controller

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Update on Propofol Shortage and Importation of Fresenius Propoven 1% (propofol 1%)

Chicago — (March 16, 2010) 

 


FDA Authorizes APP to Resume Importation of Fresenius Propoven 1% (propofol 1%) to Alleviate Ongoing Shortage of Propofol Injection in the United States

Due to the ongoing critical shortage of Propofol Injection in the United States, and in conjunction with the FDA, APP has been authorized to reintroduce Fresenius Propoven 1% (propofol 1%) to the US market. APP will also continue to offer DIPRIVAN® (propofol 1%) and increase supply of APP Propofol 1% (authorized generic DIPRIVAN).

FDA previously granted APP approval to import and distribute Fresenius Propoven 1% (propofol 1%) to help alleviate shortages following two voluntary recalls from other manufacturers of propofol injection. This temporary importation ended on February 1, 2010 and has now been reinstated to alleviate the ongoing shortage following continued supply issues from other manufacturers. APP has indicated that it is committed to providing the US market with available quantities of Fresenius Propoven 1% (propofol 1%), DIPRIVAN® (propofol 1%) and APP Propofol 1% (authorized generic DIPRIVAN®) and anticipates Fresenius Propoven (propofol 1%) will be used to address the shortage until the marketplace stabilizes. Fresenius Propoven 1% (propofol 1%) is manufactured by APP’s parent company Fresenius Kabi AG, in FDA compliant facilities.

Please see the following “Dear Healthcare Professional” letter or the FDA’s website for more information.

http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm#propofol.

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount. Join the ANESTHESIOLOGYTM 2014 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES2014.

###

Contact:

American Society of Anesthesiologists
pr@asahq.org
847-825-5586